ATE368647T1 - Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) - Google Patents
Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)Info
- Publication number
- ATE368647T1 ATE368647T1 AT03774478T AT03774478T ATE368647T1 AT E368647 T1 ATE368647 T1 AT E368647T1 AT 03774478 T AT03774478 T AT 03774478T AT 03774478 T AT03774478 T AT 03774478T AT E368647 T1 ATE368647 T1 AT E368647T1
- Authority
- AT
- Austria
- Prior art keywords
- dpp
- dipeptidyl peptidase
- inhibitors
- pharmaceutical composition
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24683102A | 2002-09-19 | 2002-09-19 | |
US10/659,860 US20040121964A1 (en) | 2002-09-19 | 2003-09-11 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE368647T1 true ATE368647T1 (de) | 2007-08-15 |
Family
ID=32033228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03774478T ATE368647T1 (de) | 2002-09-19 | 2003-09-15 | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1560811B9 (de) |
JP (1) | JP4712387B2 (de) |
KR (1) | KR101072236B1 (de) |
CN (1) | CN101676264A (de) |
AT (1) | ATE368647T1 (de) |
AU (1) | AU2003282800B2 (de) |
BR (1) | BR0314582A (de) |
CA (2) | CA2497725C (de) |
CY (1) | CY1110361T1 (de) |
DE (1) | DE60315336T2 (de) |
DK (1) | DK1560811T3 (de) |
ES (1) | ES2290511T3 (de) |
HK (1) | HK1082733A1 (de) |
IL (1) | IL167434A (de) |
MX (1) | MXPA05003091A (de) |
NZ (1) | NZ538567A (de) |
PL (1) | PL374732A1 (de) |
PT (1) | PT1560811E (de) |
TW (1) | TWI320406B (de) |
WO (1) | WO2004026822A2 (de) |
ZA (1) | ZA200502218B (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620091B1 (de) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Glutaminylcyclase-hemmer |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005023762A1 (en) * | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2005073186A1 (ja) * | 2004-01-29 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
SI1712547T1 (sl) | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Bicikloestrski derivat |
WO2005095339A1 (en) * | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
US7671073B2 (en) * | 2004-05-18 | 2010-03-02 | Merck Sharp & Dohme Corp. | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2006006065A1 (en) * | 2004-07-08 | 2006-01-19 | Warner-Lambert Company Llc | Androgen modulators |
WO2006011035A1 (en) * | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
JP2008507541A (ja) * | 2004-07-23 | 2008-03-13 | ロイヤルティ,スーザン・マリー | ペプチダーゼ阻害剤 |
EP1799639B1 (de) | 2004-10-12 | 2013-09-04 | Glenmark Pharmaceuticals S.A. | Neue dipeptidylpeptidase-iv-inhibitoren, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung |
JP2008019168A (ja) * | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | 2−シアノ−4−フルオロピロリジン誘導体の製造法 |
EP1875921A1 (de) * | 2005-04-27 | 2008-01-09 | Ajinomoto Co., Inc. | Dpp4-hemmer und seine pharmazeutische anwendung |
US20080300251A1 (en) * | 2005-09-05 | 2008-12-04 | Sattigeri Jitendra A | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors |
WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
EP1924567B1 (de) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Verfahren zur herstellung von pyrimidindionderivaten |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
AU2007224066B2 (en) | 2006-03-08 | 2011-10-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2009532454A (ja) * | 2006-04-03 | 2009-09-10 | マトリックス ラボラトリーズ リミテッド | 新規ジペプチジルペプチダーゼiv阻害因子およびその調製方法、ならび該阻害因子を含む医薬組成物 |
MX2008013130A (es) | 2006-04-12 | 2008-11-19 | Probiodrug Ag | Inhibidores de enzima. |
CN101516872A (zh) * | 2006-07-20 | 2009-08-26 | 艾博特公司 | (2s,5r)-5-乙炔基-1-{n-(4-甲基-1-(4-羧基-吡啶-2-基)哌啶-4-基)甘氨酰}吡咯烷-2-甲腈的合成 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8143427B2 (en) | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
GB2465132B (en) | 2007-09-21 | 2012-06-06 | Lupin Ltd | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
JP5476305B2 (ja) | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ[2.2.2]オクチルアミン誘導体の製造方法 |
GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EP2475428B1 (de) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocyclische derivate als glutaminylcyclase-hemmer |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
EP2544684B1 (de) * | 2010-03-10 | 2014-12-24 | Janssen Pharmaceutica NV | 4,4-disubstituierte piperidinderivate als hemmer von dipeptidylpeptidase-1 (dpp-1) |
SG183229A1 (en) | 2010-03-10 | 2012-09-27 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
TWI403716B (zh) * | 2010-08-13 | 2013-08-01 | Nat Univ Tsing Hua | 氫氣檢測器、系統及方法 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CN105601583A (zh) * | 2013-01-06 | 2016-05-25 | 天津市汉康医药生物技术有限公司 | 噻唑烷衍生物、其制备方法和用途 |
JP6590226B2 (ja) * | 2016-05-11 | 2019-10-16 | 株式会社シード探索研究所 | オキサアジリジン化合物およびその製造方法 |
EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
US5691356A (en) * | 1994-03-21 | 1997-11-25 | Bristol-Myers Squibb Company | Disubstituted heterocyclic thrombin inhibitors |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
-
2003
- 2003-09-15 EP EP03774478A patent/EP1560811B9/de not_active Expired - Lifetime
- 2003-09-15 ES ES03774478T patent/ES2290511T3/es not_active Expired - Lifetime
- 2003-09-15 JP JP2004537831A patent/JP4712387B2/ja not_active Expired - Fee Related
- 2003-09-15 DK DK03774478T patent/DK1560811T3/da active
- 2003-09-15 CA CA2497725A patent/CA2497725C/en not_active Expired - Fee Related
- 2003-09-15 DE DE60315336T patent/DE60315336T2/de not_active Expired - Lifetime
- 2003-09-15 AT AT03774478T patent/ATE368647T1/de active
- 2003-09-15 MX MXPA05003091A patent/MXPA05003091A/es active IP Right Grant
- 2003-09-15 NZ NZ538567A patent/NZ538567A/en not_active IP Right Cessation
- 2003-09-15 CA CA2768674A patent/CA2768674A1/en not_active Abandoned
- 2003-09-15 PT PT03774478T patent/PT1560811E/pt unknown
- 2003-09-15 CN CN200910166852A patent/CN101676264A/zh active Pending
- 2003-09-15 BR BR0314582-4A patent/BR0314582A/pt not_active IP Right Cessation
- 2003-09-15 AU AU2003282800A patent/AU2003282800B2/en not_active Ceased
- 2003-09-15 WO PCT/US2003/029018 patent/WO2004026822A2/en active IP Right Grant
- 2003-09-15 PL PL03374732A patent/PL374732A1/xx unknown
- 2003-09-15 KR KR1020057004773A patent/KR101072236B1/ko not_active IP Right Cessation
- 2003-09-19 TW TW092125921A patent/TWI320406B/zh not_active IP Right Cessation
-
2005
- 2005-02-16 ZA ZA2005/02218A patent/ZA200502218B/en unknown
- 2005-03-15 IL IL167434A patent/IL167434A/en not_active IP Right Cessation
-
2006
- 2006-02-09 HK HK06101745A patent/HK1082733A1/xx unknown
-
2007
- 2007-10-23 CY CY20071101364T patent/CY1110361T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05003091A (es) | 2005-05-27 |
PL374732A1 (en) | 2005-10-31 |
EP1560811B9 (de) | 2008-03-05 |
CN101676264A (zh) | 2010-03-24 |
IL167434A (en) | 2010-12-30 |
KR101072236B1 (ko) | 2011-10-12 |
EP1560811B1 (de) | 2007-08-01 |
ZA200502218B (en) | 2005-11-30 |
JP4712387B2 (ja) | 2011-06-29 |
ES2290511T3 (es) | 2008-02-16 |
CA2497725C (en) | 2012-04-10 |
JP2006503057A (ja) | 2006-01-26 |
DE60315336T2 (de) | 2008-05-08 |
CA2497725A1 (en) | 2004-04-01 |
DE60315336D1 (de) | 2007-09-13 |
CY1110361T1 (el) | 2015-04-29 |
NZ538567A (en) | 2007-04-27 |
PT1560811E (pt) | 2007-11-14 |
EP1560811A2 (de) | 2005-08-10 |
DK1560811T3 (da) | 2007-12-10 |
WO2004026822A2 (en) | 2004-04-01 |
AU2003282800A1 (en) | 2004-04-08 |
TWI320406B (en) | 2010-02-11 |
AU2003282800B2 (en) | 2009-10-29 |
HK1082733A1 (en) | 2006-06-16 |
CA2768674A1 (en) | 2004-04-01 |
BR0314582A (pt) | 2005-08-09 |
KR20050043981A (ko) | 2005-05-11 |
WO2004026822A3 (en) | 2004-05-06 |
TW200417545A (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE368647T1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
BR0315796A (pt) | Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero | |
MXPA04003759A (es) | Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv. | |
EP1554280A4 (de) | Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase | |
ATE419848T1 (de) | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 | |
CL2004000437A1 (es) | Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast | |
EP1490335A4 (de) | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes | |
ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
EP1819674A4 (de) | Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes | |
WO2004037181A3 (en) | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods | |
HUP0303876A3 (en) | Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv | |
DE602004026440D1 (de) | Kondensierte indole als dipeptidyl-peptidase-hemmer zur behandlung oder prävention von diabetes | |
WO2004050022A8 (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
DE60209348D1 (de) | Dipeptidylpeptidase-hemmer zur behandlung von diabetes | |
EP1651623A4 (de) | Hexahydrodiazepinone als inhibitoren von dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes | |
ATE396190T1 (de) | Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase | |
HK1100559A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
MXPA05001712A (es) | Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b. | |
SG141430A1 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
TW200500338A (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1560811 Country of ref document: EP |